Display options
Share it on

Curr Treat Options Cardiovasc Med. 2014 Aug;16(8):330. doi: 10.1007/s11936-014-0330-5.

Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.

Current treatment options in cardiovascular medicine

Simon F Shakar, JoAnn Lindenfeld

Affiliations

  1. University of Colorado Denver, Box B130, 12631 East 17th Avenue, Aurora, CO, 80045, USA, [email protected].

PMID: 25063583 DOI: 10.1007/s11936-014-0330-5

Abstract

OPINION STATEMENT: Most patients admitted to the hospital with ADHF do not achieve adequate relief of signs and symptoms of congestion. Patients with inadequate decongestion are known to be at higher risk of readmission for heart failure and mortality, although it is uncertain whether this is a cause or simply a marker of increased risk. Nonetheless, adequate decongestion is critical for improving quality of life. Based on the DOSE-AHF and CARRESS-HF studies, a high-dose diuretic regimen consisting of 2.5 times the daily dose of loop diuretic in furosemide equivalents, administered in twice-daily bolus doses, is reasonable to achieve a goal of 3-5 liters of urine output per day. Transient increases in creatinine in the first 4-5 days of diuresis should not be a limiting factor, but a prolonged progressive increase in creatinine signals a high-risk patient. Current goals for decongestion should be resolution of orthopnea, jugular venous pressure of < 8 cm of water, and trace to no peripheral edema. The hope is that better measures of assessing complete decongestion will reduce the progression to heart failure and mortality. While the best noninvasive method to assess speed of congestion has not been determined, it is clear that hemoconcentration (an increase in hematocrit) reflects a decrease in plasma volume and decongestion. In-line monitoring of hemoconcentration may improve the results of ultrafiltration therapy by preventing too large and/or too rapid a fall in intravascular volume and consequent triggering of neurohormonal activation. Several additional strategies such as serelaxin, high-dose mineralocorticoid receptor antagonists, and new forms and combinations of natriuretic peptides have shown promising results in the relief of congestion in patients with ADHF.

References

  1. J Am Coll Cardiol. 2013 May 14;61(19):1973-81 - PubMed
  2. J Palliat Med. 2011 Jun;14(6):735-43 - PubMed
  3. Eur Heart J. 2003 Mar;24(5):442-63 - PubMed
  4. Eur J Heart Fail. 2013 Apr;15(4):433-40 - PubMed
  5. Eur J Heart Fail. 2005 Oct;7(6):953-7 - PubMed
  6. Lancet. 2013 Jan 5;381(9860):29-39 - PubMed
  7. Circ Heart Fail. 2014 Jan;7(1):59-67 - PubMed
  8. Circ Heart Fail. 2009 Jul;2(4):370-6 - PubMed
  9. J Am Coll Cardiol. 2008 Nov 4;52(19):1527-39 - PubMed
  10. Circ Heart Fail. 2011 Sep;4(5):669-75 - PubMed
  11. N Engl J Med. 1988 Oct 27;319(17):1127-34 - PubMed
  12. JAMA. 2005 Oct 5;294(13):1625-33 - PubMed
  13. Eur J Heart Fail. 2010 May;12(5):423-33 - PubMed
  14. Circulation. 2003 Jan 21;107(2):226-9 - PubMed
  15. N Engl J Med. 2010 Oct 7;363(15):1419-28 - PubMed
  16. J Card Fail. 2012 Mar;18(3):176-82 - PubMed
  17. N Engl J Med. 2010 Dec 9;363(24):2301-9 - PubMed
  18. J Card Fail. 2010 Jul;16(7):541-7 - PubMed
  19. JAMA. 2007 Mar 28;297(12):1332-43 - PubMed
  20. Ann Intern Med. 1985 Jul;103(1):1-6 - PubMed
  21. J Am Coll Cardiol. 2013 Aug 6;62(6):516-24 - PubMed
  22. Circulation. 2010 Jul 20;122(3):265-72 - PubMed
  23. N Engl J Med. 2011 Mar 3;364(9):797-805 - PubMed
  24. Circulation. 1965 Aug;32:223-31 - PubMed
  25. Circ Heart Fail. 2012 Jan;5(1):54-62 - PubMed
  26. Am Heart J. 2005 Feb;149(2):209-16 - PubMed
  27. JAMA. 2002 Mar 27;287(12):1531-40 - PubMed
  28. JAMA. 2013 Dec 18;310(23):2533-43 - PubMed
  29. JAMA. 2006 Nov 8;296(18):2217-26 - PubMed
  30. Circulation. 1989 Aug;80(2):299-305 - PubMed
  31. Am Heart J. 2004 Feb;147(2):331-8 - PubMed
  32. Am J Nephrol. 1991;11(6):441-6 - PubMed
  33. Am J Cardiol. 1990 Dec 1;66(19):1348-54 - PubMed
  34. J Am Coll Cardiol. 2008 Apr 1;51(13):1268-74 - PubMed
  35. N Engl J Med. 2012 Dec 13;367(24):2296-304 - PubMed
  36. Circ Heart Fail. 2013 Mar;6(2):240-5 - PubMed
  37. J Card Fail. 2010 Jun;16(6):e1-194 - PubMed
  38. Eur J Heart Fail. 2011 Aug;13(8):877-84 - PubMed
  39. Circulation. 2008 Sep 30;118(14):1433-41 - PubMed
  40. Curr Cardiol Rep. 2012 Jun;14(3):254-64 - PubMed
  41. Eur J Heart Fail. 2013 Apr;15(4):456-64 - PubMed
  42. JAMA. 2007 Mar 28;297(12):1319-31 - PubMed
  43. J Am Coll Cardiol. 2004 May 5;43(9):1534-41 - PubMed
  44. J Am Coll Cardiol. 2012 Sep 18;60(12):1031-42 - PubMed
  45. Am Heart J. 2000 Dec;140(6):840-7 - PubMed
  46. Cardiorenal Med. 2013 Apr;3(1):1-6 - PubMed
  47. J Card Fail. 2005 Apr;11(3):200-5 - PubMed
  48. Circulation. 2004 Oct 19;110(16):2389-94 - PubMed
  49. Eur Heart J. 2006 May;27(10):1207-15 - PubMed
  50. J Hosp Med. 2012 Mar;7(3):270-5 - PubMed
  51. Am J Cardiol. 1993 Jan 21;71(3):21A-28A - PubMed
  52. Curr Treat Options Cardiovasc Med. 2001 Apr;3(2):151-159 - PubMed
  53. Circ Heart Fail. 2013 May;6(3):594-605 - PubMed
  54. Kidney Int Suppl. 1999 Nov;(72):S8-14 - PubMed
  55. Circ Heart Fail. 2013 Mar;6(2):264-70 - PubMed
  56. N Engl J Med. 2011 Jul 7;365(1):32-43 - PubMed

Publication Types